Share
17 March 202019.25 The director of the Italian drug agency, Nicola Magrini, announces the "experimentation of tocilizumab, a drug for rheumatoid arthritis". "The preliminary data are promising. The study will be on 330 patients and will start on Thursday to evaluate the impact of the drug," explains Magrini. The study is promoted by the National Institute for the Study and Treatment of Cancer in Naples, with the University of Modena and Reggio Emilia, the IRCCS of Reggio Emilia and Aifa.Virus, Aifa: anti-arthritis drug tested
2020-03-17T18:41:08.532Z
- Violence and Vandalism Erupt Between PSG and OL Supporters: Toll Booth Damaged
- Ligue 1's Anti-Homophobia Campaign Faces Controversy Amid Player Actions
- Notorious Grenoble Trafficker Acquitted Posthumously; Tragic Double Life Unveiled
- Grenade Attack in Aubervilliers: Two Injured in Explosive Incident Tied to Drug Trafficking
- Arcom Slaps CNews with €50,000 Fine Over Anti-Semitic Remarks Linking 'Arab-Muslim Immigration'
19.25 The director of the Italian drug agency, Nicola Magrini, announces the "trial of tocilizumab, a drug for rheumatoid arthritis". "The preliminary data are promising. The study will be on 330 patients and will start on Thursday to evaluate the impact of the drug," explains Magrini. The study is promoted by the National Institute for the Study and Treatment of Cancer in Naples, with the University of Modena and Reggio Emilia, the IRCCS of Reggio Emilia and Aifa.
Source: rainews